RUBY - Rubius: Early Positive Data But Stretched Valuation May, 20 2021 05:42 AM Rubius Therapeutics Inc. Rubius just released some early data at the AACR. The data was good, but at $2.37bn market cap, RUBY is overvalued. I will wait for more data and a better price. For further details see: Rubius: Early Positive Data, But Stretched Valuation